Ironwood Pharmaceuticals (IRWD) Competitors $0.74 +0.00 (+0.04%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, ZBIO, RIGL, EBS, XOMA, CBIO, LXRX, VNDA, VSTM, and CDXSShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Codexis (CDXS). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Zenas BioPharma Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Crescent Biopharma Lexicon Pharmaceuticals Vanda Pharmaceuticals Verastem Codexis AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment. Do institutionals & insiders have more ownership in ABBV or IRWD? 70.2% of AbbVie shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ABBV or IRWD more profitable? AbbVie has a net margin of 7.31% compared to Ironwood Pharmaceuticals' net margin of -9.89%. AbbVie's return on equity of 412.03% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AbbVie7.31% 412.03% 13.11% Ironwood Pharmaceuticals -9.89%-1.87%-3.93% Which has better earnings & valuation, ABBV or IRWD? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B5.94$4.28B$2.3580.64Ironwood Pharmaceuticals$351.41M0.34$880K-$0.20-3.70 Does the media favor ABBV or IRWD? In the previous week, AbbVie had 107 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 108 mentions for AbbVie and 1 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.08 beat Ironwood Pharmaceuticals' score of 0.00 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 71 Very Positive mention(s) 14 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ABBV or IRWD? AbbVie has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Do analysts prefer ABBV or IRWD? AbbVie presently has a consensus target price of $211.29, indicating a potential upside of 11.50%. Ironwood Pharmaceuticals has a consensus target price of $4.78, indicating a potential upside of 546.40%. Given Ironwood Pharmaceuticals' higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.81Ironwood Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryAbbVie beats Ironwood Pharmaceuticals on 15 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.70M$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-3.708.8627.4020.04Price / Sales0.34680.42419.46118.60Price / Cash14.95157.0736.6357.47Price / Book-0.394.638.085.67Net Income$880K$31.34M$3.16B$248.47M7 Day Performance-4.91%0.84%2.12%2.90%1 Month Performance21.33%7.92%4.43%5.75%1 Year Performance-87.89%1.87%35.62%21.36% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.6466 of 5 stars$0.74+0.0%$4.78+546.4%-88.1%$119.70M$351.41M-3.70220ABBVAbbVie4.9069 of 5 stars$185.80+1.9%$211.29+13.7%+14.9%$322.03B$56.33B79.0655,000Trending NewsAnalyst RevisionZBIOZenas BioPharma1.6622 of 5 stars$9.69+1.1%$36.67+278.4%N/A$400.77M$5M-2.73N/AGap UpRIGLRigel Pharmaceuticals2.8517 of 5 stars$18.73-3.9%$36.40+94.3%+121.5%$348.15M$179.28M9.05160EBSEmergent Biosolutions4.0015 of 5 stars$6.38+0.5%$14.33+124.7%-5.5%$344.66M$1.04B-2.352,420XOMAXOMA Royalty4.4356 of 5 stars$25.20-8.3%$69.50+175.8%+6.0%$328.97M$28.49M-21.9110High Trading VolumeCBIOCrescent Biopharma3.2961 of 5 stars$16.14+1.5%$25.00+54.9%N/A$310.84M$10K0.0026News CoverageLXRXLexicon Pharmaceuticals2.5184 of 5 stars$0.95+15.2%$3.67+287.7%-42.8%$296.75M$31.08M-1.85140News CoverageVNDAVanda Pharmaceuticals4.4178 of 5 stars$4.72-1.3%$16.50+249.6%-7.2%$281.71M$198.77M-6.29290VSTMVerastem2.8666 of 5 stars$4.15flat$13.38+222.3%+65.2%$228.04M$10K-1.3050CDXSCodexis3.092 of 5 stars$2.44+2.1%$11.00+350.8%-2.8%$198M$59.35M-2.46250Positive News Related Companies and Tools Related Companies AbbVie Alternatives Zenas BioPharma Alternatives Rigel Pharmaceuticals Alternatives Emergent Biosolutions Alternatives XOMA Royalty Alternatives Crescent Biopharma Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
